An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer‘s disease—A cohort study of 95,442 individuals
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Introduction: We tested the hypothesis that low plasma complement C3 is observationally and genetically associated with high risk of Alzheimer's disease (AD). Methods: We studied 95,442 individuals enrolled in the Copenhagen General Population Study. In genetic analyses, we further included 8367 individuals from the Copenhagen City Heart Study. In the two studies, 1189 and 35 developed AD during median 8 years follow‐up. Results: The multifactorially adjusted hazard ratio for risk of AD for a one standard deviation lower levels of complement C3 was 1.11 (95% confidence interval: 1.04–1.19) in all individuals and 1.66 (1.33–2.07) in APOE ε44 carriers. In Mendelian randomization, the corresponding genetic estimates were 1.66 (1.05–2.63) overall and 1.99 (0.52–7.65) in APOE ε44 carriers. Discussion: Low baseline levels of complement C3 were associated with high risk of AD. The risk was amplified in APOE ε44 highly susceptible individuals, and these findings were substantiated by a Mendelian randomization approach, potentially implying causality. Based on these findings, we present and thoroughly discuss an updated Alzheimer hypothesis incorporating low complement C3 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 2×
“As synaptic loss is a pathological correlate of cognitive decline and occurs in mild cognitive impairment and AD before onset of plaques [10,36], this may either drive or contribute to the early preclinical pathogenesis of AD.”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Finally, in the cholinergic system [58,59], loss of complement-mediated clearance of amyloid-b and subsequent buildup may disrupt neuronal function [60], as cholinergic neurotransmitters may be specific targets for amyloid-b and as its presence has been shown to reduce both choline uptake and acetylcholine release [61…”
ResultDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Second, low complement C3 may cause reduced clearance of amyloid-b from the systemic circulation in AD [37].”
BackgroundGenetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“For Alzheimer pathology driven by the immune system, infection, and inflammation, complement activation serves a central role in the innate immune system, and complement factors interact with glia cells, although details of the mechanisms are still unknown [9,13,48,53].”
BackgroundResultIncidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“For Alzheimer pathology driven by the immune system, infection, and inflammation, complement activation serves a central role in the innate immune system, and complement factors interact with glia cells, although details of the mechanisms are still unknown [9,13,48,53].”
BackgroundGlucose Levels and Risk of Dementia
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215740 · Cited by 929 · cited 1×
“Metabolic dysfunction is involved in AD [62], and complement activation plays a role in metabolic dysfunction [17].”
BackgroundA Comparison of the Prevalence of Dementia in the United States in 2000 and 2012
Langa, K. M., Larson, E. B., Crimmins, E. M., Faul, J. D., Levine, D. A., Kabeto, M. U., & Weir, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6807 · Cited by 910
Cholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839 · cited 1×
“The epidemiological findings were substantiated byMendelian randomization where plasma complement C3 determining genotypes, combined into a weighted or a simple gene score, were used to predict risk of AD based on the epidemiological associations, and subsequently, compared with the observational risk of AD, as done p…”
MethodSelf-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism
Mahley, R. W. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307023 · Cited by 516
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Self-citationImmunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454 · cited 2×
“All of these mechanisms evolve around the central metabolism of amyloid-b and tau [66,67], and the updated Alzheimer hypothesis presented in this article may potentially be linked, as complement factors are found in amyloid plaques and as tau is an activator of the complement system [30,34].”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 5×
“Finally, deficiency of complement C3 (by C32/2 knockout) or a relative inhibition of complement C3 was associated with AD–related measurements in mice models [11,12].”
BackgroundResultInfluentialJun, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.201 · Cited by 422
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410 · cited 1×
“Of the remaining overlapping mechanisms, not at this point known to interact with the complement system, but still contributing to the Alzheimer syndrome: endocytosis [63,64], oxidative stress, and mitochondrial dysfunction [58,65].”
BackgroundActivation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383 · cited 2×
“Does the putative theory provide a plausible explanation for the anatomical specificity of early lesions associated with the syndrome? Given such compensatory inefficacious upregulation in later clinical overt stages of disease [11,12], this fits very well with previous studies both with regard to the temporal order a…”
BackgroundResultBeecham, G. W., Hamilton, K., Naj, A. C., Martin, E. R., Huentelman, M., Myers, A. J., Corneveaux, J. J., Hardy, J., Vonsattel, J.-P., Younkin, S. G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004606 · Cited by 343
Maier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323 · cited 5×
“Finally, deficiency of complement C3 (by C32/2 knockout) or a relative inhibition of complement C3 was associated with AD–related measurements in mice models [11,12].”
BackgroundResultInfluentialAlzheimer's Association Calcium Hypothesis Workgroup, & Khachaturian, Z. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.006 · Cited by 311
Ahmadi-Abhari, S., Guzman-Castillo, M., Bandosz, P., Shipley, M. J., Muniz-Terrera, G., Singh-Manoux, A., Kivimäki, M., Steptoe, A., Capewell, S., O’Flaherty, M., et al. (2017) · BMJ · doi:10.1136/bmj.j2856 · Cited by 301
Validity of Dementia Diagnoses in the Danish Hospital Registers
Phung, T. K. T., Andersen, B. B., Høgh, P., Kessing, L. V., Mortensen, P. B., & Waldemar, G. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107084 · Cited by 279 · cited 1×
“One potential limitation concerns the availability and completeness of the diagnostic information; however, the Danish Patient Registry includes all hospital visits, as well as out-patient visits, and it has previously been shown that the dementia diagnoses in the Danish Registries have high diagnostic validity [70],…”
BackgroundChen, H.-K., Ji, Z.-S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.151084 · Cited by 209 · cited 1×
“Of the remaining overlapping mechanisms, not at this point known to interact with the complement system, but still contributing to the Alzheimer syndrome: endocytosis [63,64], oxidative stress, and mitochondrial dysfunction [58,65].”
BackgroundNaj, A. C., Jun, G., Reitz, C., Kunkle, B. W., Perry, W., Park, Y. S., Beecham, G. W., Rajbhandary, R. A., Hamilton-Nelson, K. L., Wang, L.-S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1491 · Cited by 185
Complement activation by neurofibrillary tangles in Alzheimer's disease
Shen, Y., Lue, L.-F., Yang, L.-B., Roher, A., Kuo, Y.-M., Strohmeyer, R., Goux, W. J., Lee, V., Johnson, G. V. W., Webster, S. D., et al. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01842-0 · Cited by 185 · cited 2×
“Also, both amyloid-b and tau protein have been shown to activate the classical complement pathway [33,34].”
BackgroundLanger, H. F., Chung, K.-J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., DeAngelis, R. A., Roche, P. A., Magotti, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261503 · Cited by 176
Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
Self-citationWhy lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.05.006 · Cited by 75
Self-citation
Cited by
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Carpanini, S. M., Torvell, M., & Morgan, B. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00362 · Cited by 207
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Carpanini, S. M., Torvell, M., Bevan, R. J., Byrne, R. A. J., Daskoulidou, N., Saito, T., Saido, T. C., Taylor, P. R., Hughes, T. R., Zelek, W. M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01404-w · Cited by 95
Associations of Alzheimer Disease–Protective APOE Variants With Age-Related Macular Degeneration
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.4602 · Cited by 40
Self-citation
Metadata
- Authors
- Rasmussen, K. L., Nordestgaard, B. G., Frikke‐Schmidt, R., & Nielsen, S. F.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-09-19
- Volume
- 14
- Issue
- 12
- Pages
- 1589-1601
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2892196137
- Cited by
- 53
- References
- 40
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.